Results 71 to 80 of about 9,980 (152)

Severe hypokalemia induced by ceftazidime-avibactam: Case report. [PDF]

Medicine (Baltimore)
Yuan Y, Gu Y, Bai W, Liu W, Li W, Yin Y.
europepmc   +1 more source

In vitro activity of aztreonam/avibactam and comparators against Enterobacterales isolates from patients with hospital-acquired pneumonia, ventilator-associated pneumonia, and complicated intra-abdominal infections (ATLAS, 2021-2022). [PDF]

J Antimicrob Chemother
Yang Q, Tuon FF, Shah S, Kamat S, Mohamed N, Stone GG, Perez KK, Cantón R.   +7 more
europepmc   +1 more source

Evaluating the efficacy of ceftazidime/avibactam plus amikacin combination therapy as a carbapenem-sparing agent against ceftazidime/avibactam-resistant <i>Escherichia coli</i> using a hollow fiber infection model: a proof-of-concept study. [PDF]

Antimicrob Agents Chemother
Walker MM, Roberts JA, Li Y, Naicker S, Wallis SC, Ordonez JL, Won H, Forde BM, Sime FB.   +8 more
europepmc   +1 more source

Emergence of Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae with Penicillin-Binding Protein 3 Insertions, Taiwan, 2021. [PDF]

Emerg Infect Dis
Long T, Lovey A, Sanborn L, Zhao Y, Bulman ZP, Lin YT, Chen L.   +6 more
europepmc   +1 more source

Combination Therapy with Ceftazidime-Avibactam, Aztreonam, and Topical Polymyxin B for NDM-Producing <i>Klebsiella pneumoniae</i> CNS Infection: A Case Report. [PDF]

Infect Drug Resist
Qi G, Cong W, Zhang M, Wang S, Bai Z, Li B, Chen H.   +6 more
europepmc   +1 more source

<i>In vitro</i> activity of aztreonam-nacubactam and cefepime-nacubactam against a global collection of clinically important Gram-negative Bacilli collected in 2021-2023. [PDF]

JAC Antimicrob Resist
Karlowsky JA, Estabrook M, Suzuki E, Shimizu A, Okade H.   +4 more
europepmc   +1 more source

Comparison of laboratory-developed methods for aztreonam plus ceftazidime-avibactam antimicrobial susceptibility testing for metallo-beta-lactamase-producing Enterobacterales. [PDF]

J Clin Microbiol
Bhatnagar AS, Harris H, Jacobs E, Bumpus-White P, Balbuena R, Stambaugh H, Crayton K, Haynie J, Quintero Ilutsik J, Longo C, Bergman Y, Singh S, Murray M, Sabour S, Robinson ML, Machado M-J, Simner PJ.   +16 more
europepmc   +1 more source

PK/PD-guided ceftazidime-avibactam dosing for multidrug-resistant <i>Pseudomonas aeruginosa</i> infection in a preterm infant with chylothorax and ascites: a case report. [PDF]

Front Pharmacol
Yuan W, Zhao X, Liu X, Tao X, Zeng L.
europepmc   +1 more source

Disease severity modifies the ceftazidime-avibactam exposure-response relationship in critically ill patients: a retrospective study. [PDF]

Front Pharmacol
Qian S, Xu D, Xu Y, Qi H, Liang P.
europepmc   +1 more source

Contemporary multicentre analysis of carbapenemases distribution among clinical carbapenem-resistant Enterobacterales in Lebanon. [PDF]

JAC Antimicrob Resist
Tannous J, Saliba R, Mghames A, Tokajian S, Attieh R, Jisr T, Barhoun J, Diab MK, Shakra DA, Mokhbat J, Al Souheil A, Zorkot W, Jaffal F, Salman H, Husni R, Rahban H, Khoury E, Mohsen Z, Abboud E, Youssef M, Karayakoupoglo G, Fawaz I, Houmani M, Abdallah D, Moghnieh R.   +24 more
europepmc   +1 more source